0001770141-24-000020.txt : 20240318 0001770141-24-000020.hdr.sgml : 20240318 20240318083051 ACCESSION NUMBER: 0001770141-24-000020 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240315 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240318 DATE AS OF CHANGE: 20240318 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UpHealth, Inc. CENTRAL INDEX KEY: 0001770141 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 833838045 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38924 FILM NUMBER: 24757005 BUSINESS ADDRESS: STREET 1: 14000 S. MILITARY TRAIL STREET 2: SUITE 203 CITY: DELRAY BEACH STATE: FL ZIP: 33484 BUSINESS PHONE: 888.424.3646 MAIL ADDRESS: STREET 1: 14000 S. MILITARY TRAIL STREET 2: SUITE 203 CITY: DELRAY BEACH STATE: FL ZIP: 33484 FORMER COMPANY: FORMER CONFORMED NAME: GigCapital2, Inc. DATE OF NAME CHANGE: 20190308 8-K 1 uph-20240315.htm 8-K uph-20240315
0001770141false00017701412024-03-152024-03-15

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

March 15, 2024
Date of Report (date of earliest event reported)

UpHealth, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
 of incorporation or organization)
001-38924
(Commission
 File Number)
83-3838045
(I.R.S. Employer
 Identification Number)
14000 S. Military Trail, Suite 203
Delray Beach, FL 33484
(Address of principal executive offices, including zip code)
(888) 424-3646
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
 Symbols
Name of each exchange
on which registered
Common Stock, par value $0.0001 per share
UPH(1)
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 







___________________________________________________
(1)On December 11, 2023, UpHealth, Inc. (the “Company”) received written notice from the staff of NYSE Regulation that it has commenced proceedings to delist the common stock, par value $0.0001 per share, of the Company (ticker symbol: UPH) (the “Common Stock”), from the New York Stock Exchange (“NYSE”), and suspended trading in the Common Stock pending the completion of such proceedings. As a result, effective December 12, 2023, the Common Stock is trading in the over-the-counter market under the symbol “UPHL”. The Company timely filed an appeal of this determination with the NYSE and requested a hearing before the NYSE Regulatory Oversight Committee’s Committee for Review. On January 12, 2024, the NYSE granted the Company’s request for a hearing, which is expected to take place on April 17, 2024.




Item 2.01
Completion of Acquisition or Disposition of Assets.

As disclosed in the Current Report on Form 8-K filed by UpHealth, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on November 20, 2023 (the “November 20 Current Report”), on November 16, 2023, the Company and its wholly-owned subsidiary, Cloudbreak Health, LLC, a Delaware limited liability company (“Cloudbreak”), entered into a membership interests purchase agreement (the “Purchase Agreement”) with Forest Buyer, LLC, a Delaware limited liability company (“Forest Buyer”) and an affiliate of GTCR LLC, a leading private equity firm, pursuant to which the Company agreed to sell all of the outstanding equity interests of Cloudbreak and the wholly-owned subsidiaries of Cloudbreak to Forest Buyer for $180.0 million in cash, subject to certain adjustments for closing indebtedness, net working capital, cash and unpaid transaction expenses related to the transactions contemplated by the Purchase Agreement (the “Sale” and all of the transactions contemplated by the Purchase Agreement, collectively, the “Transactions”), as more fully described in the Company’s definitive proxy statement filed with the SEC on January 24, 2024.

As further disclosed in the November 20 Current Report, in connection and concurrently with the entry into the Purchase Agreement, the Company, Cloudbreak and Forest Buyer entered into a transaction support agreement, dated as of November 16, 2023 (the “Transaction Support Agreement”), with certain beneficial holders of the Company’s Variable Rate Convertible Senior Secured Notes due 2025 (“2025 Notes”) (being the holders of at least 69% of the 2025 Notes, the “Consenting 2025 Noteholders”) and certain beneficial holders of the Company’s 6.25% Convertible Senior Notes due 2026 (“2026 Notes”) (being the holders of at least 88% of the 2026 Notes, the “Consenting 2026 Noteholders”, and together with the Consenting Senior Secured Noteholders, the “Consenting Noteholders”), pursuant to which the parties thereto agreed, among other things, to support the Purchase Agreement and the Transactions, including the Sale, and to enter into and effect the Supplemental Indentures (as defined below) in connection with the offers to repurchase the 2025 Notes and the 2026 Notes in accordance with the terms of the applicable Indenture as a result of any or all of the Transactions constituting a Fundamental Change (as such term is defined in each of the Indentures) under the applicable Indenture (each, a “Fundamental Change Repurchase Offer”) to be made by the Company pursuant to the terms of the Transaction Support Agreement.

Furthermore, as disclosed in the Current Report on Form 8-K filed by the Company with the SEC on February 15, 2024 (the “February 15 Current Report”), on February 9, 2024, in accordance with the terms of the Purchase Agreement and the Transaction Support Agreement, the Company entered into a supplemental indenture and amendment to security and pledge agreement, dated as of February 9, 2024 (the “First Lien Supplemental Indenture and Amendment to Security Agreement”), which amended the terms of the indenture, dated as of August 18, 2022, by and among the Company, the Guarantors (as defined below) party thereto and Wilmington Trust, National Association (“Wilmington Trust”), in its capacity as trustee and collateral agent thereunder, relating to the 2025 Notes (as amended, restated, supplemented or otherwise modified from time to time, including pursuant to the First Lien Supplemental Indenture and Amendment to Security Agreement as described below, the “First Lien Indenture”), and the security and pledge agreement, dated as of August 18, 2022, by and among the Company, the Guarantors from time to time party thereto and Wilmington Trust, as collateral agent, relating to the 2025 Notes (as amended, restated, supplemented or otherwise modified from time to time, including pursuant to the First Lien Supplemental Indenture and Amendment to Security Agreement as described below, the “First Lien Security Agreement” and together with the First Lien Indenture, the “First Lien Documents”). The First Lien Supplemental Indenture and Amendment to Security Agreement amended the terms of the First Lien Indenture to, among other things, (a) provide for certain changes to certain of the definitions in the First Lien Indenture, including “Permitted Indebtedness”, “Permitted Investments”, “Permitted Liens”, “Asset Sale”, “Excluded Subsidiary” and “Significant Subsidiary” (b) provide for certain modifications to covenants of the Company and certain changes with respects to events of default; (c) provide a carveout for the Sale from the terms of the First Lien Indenture with respect to mergers and sale transactions; (d) delete the rule prohibiting repurchases in connection with a Fundamental Change arising from the Sale at the time the 2025 Notes have been accelerated, and (e) modify the provisions in respect of repurchases of 2025 Notes as a result of a Fundamental Change for the Consenting 2025 Noteholders in respect of the Sale to account for a multi-step process for the repurchase of the 2025 Notes (i.e., to require a repurchase offer at Closing and in connection with subsequent paydowns with the proceeds of released funds from the Escrow Accounts (as defined below)), in each case, at a 5.00% premium to the principal amount of such 2025 Notes pursuant to the terms of the Transaction Support Agreement.

In addition, as disclosed in the February 15 Current Report, on February 9, 2024, in accordance with the terms of the Purchase Agreement and the Transaction Support Agreement, the Company entered into a supplemental indenture (the “Second Lien Supplemental Indenture” and together with the First Lien Supplemental Indenture, the “Supplemental Indentures”) to the indenture, dated June 9, 2021, by and between the Company and The Bank of New York Mellon Trust Company, N.A. (“BNY Mellon”), in its capacity as successor trustee and as collateral agent thereunder (as amended, restated, supplemented or otherwise modified from time to time, including pursuant to the Second Lien Supplemental Indenture and the Second Lien Security Agreement as described below, the “Second Lien Indenture” and together with the First Lien Indenture, the “Indentures”), the terms of which amended the Second Lien Indenture to, among other things, (a) add each subsidiary of UpHealth, other than Glocal Healthcare Systems Private Limited, UPH Digital Health Services Private Limited and any subsidiary of UpHealth that is, as of the date of the Supplemental Indentures, a debtor or debtor in possession in any bankruptcy proceeding, including the jointly administered Chapter 11 proceedings pending before the United States Bankruptcy Court for the District of Delaware under caption In re UpHealth Holdings, Inc., Case No. 23-11476-LSS (collectively, the “Guarantors”), as a guarantor of the obligations under the 2026 Notes pursuant to the Second Lien Indenture; (b) cause UpHealth and the Guarantors to grant a second-priority security interest on the same collateral that secures the 2025 Notes; (c) in connection with those items described in clauses (a) and (b) above, incorporate provisions similar to those in the First Lien Indenture, including with respect to covenants and events of default, as previously disclosed by the Company and as modified by the First Lien Supplemental Indenture; and (d) provide a carveout for the Sale from the terms of the Second Lien Indenture with respect to mergers and sale transactions. Pursuant to the terms of the Second Lien Indenture, the 2026 Notes are secured by a second-priority lien, subject only to certain permitted liens, in substantially all assets of the Company and the Guarantors, subject to customary exclusions, pursuant to a security and pledge agreement,


dated as of February 9, 2024 (as it may be amended, modified, or supplemented from time to time, the “Second Lien Security Agreement” and together with the Second Lien Indenture, the “Second Lien Documents”), by and among the Company, the Guarantors and BNY Mellon, as collateral agent on behalf of the 2026 Noteholders.

Furthermore, as disclosed in the Current Report on Form 8-K filed by the Company with the SEC on March 1, 2024, at a special meeting of the Company’s stockholders held on February 29, 2024, the stockholders approved the Purchase Agreement providing for the Sale of Cloudbreak and the wholly-owned subsidiaries of Cloudbreak to Forest Buyer, as such Sale constitutes the sale of substantially all of the assets of the Company under Delaware law.

Closing of the Sale of Cloudbreak

On March 15, 2024 (the “Closing Date”), the Company completed the closing of the Transactions (the “Closing”). In connection and concurrently with the Closing, Cloudbreak and its subsidiaries were released as Guarantors under the First Lien Documents and the Second Lien Documents. Pursuant to the terms of the Purchase Agreement, the “Cash Consideration” for the Sale was an amount equal to $180.0 million, with adjustments for debt as of immediately prior to the Closing and cash as of 11:59 p.m. (Delray Beach, Florida time) on the day immediately prior to the Closing Date (the “Calculation Time”), Cloudbreak’s net working capital as of the Calculation Time, and unpaid expenses related to the Transactions. The consideration payable for the benefit of the Company at the Closing was $180.0 million, less adjustments for the estimated closing debt and cash and the estimated unpaid expenses related to the Transactions (the “Estimated Cash Consideration”). All of the Estimated Cash Consideration was delivered by Forest Buyer to an escrow agent (the “Escrow Agent”) and deposited into three segregated escrow accounts established pursuant an escrow agreement, dated March 15, 2024, entered into in accordance with the terms of the Purchase Agreement by the Company, Forest Buyer and the Escrow Agent (the “Escrow Agreement”), as follows: (i) $3 million (the “Working Capital Escrow Amount”) was deposited in a segregated escrow account to satisfy any adjustment to the Cash Consideration (the “Working Capital Escrow Account”); (ii) $27 million (the “Tax Escrow Amount”) was deposited in a segregated escrow account to enable the Company to pay any and all taxes that become due and payable by the Company as a result of the Transactions (the “Tax Escrow Account”); and (iii) the remaining portion of the Estimated Cash Consideration equal to approximately $139 million (such amount, the “Notes Escrow Amount”), was deposited in a segregated escrow account (the “Notes Escrow Account”, and together with the Working Capital Escrow Account and the Tax Escrow Account, the “Escrow Accounts”), the purpose of which is to fund the Fundamental Change Repurchase Offers. The funds in the Notes Escrow Account will be released on approximately June 3, 2024, but no later than June 15, 2024, and will be used to satisfy in full, plus accrued interest, the 2026 Notes and to repurchase approximately $20 million of the 2025 Notes, plus accrued interest, following which approximately $37 million in aggregate principal amount of 2025 Notes will remain outstanding, which will constitute the entirety of the Company’s outstanding long term debt. Funds in the Tax Escrow Account will be used to satisfy the Company’s 2024 tax liability in respect of the Transactions and any funds not required for this purpose will be used to repurchase additional 2025 Notes. Funds in the Working Capital Escrow Account will be used to satisfy any obligations of the Company resulting from a difference between Cloudbreak’s targeted and actual working capital as of the Closing, and any funds not used for this purpose will be used to repurchase additional 2025 Notes.

Following the Closing, in connection with a customary adjustment to the Cash Consideration, which adjustment is expected, in the absence of any disagreement, to be determined within 120 days following the Closing Date, to the extent that the Cash Consideration exceeds the Estimated Cash Consideration, a payment shall be made for the purpose of repurchasing the 2026 Notes and/or the 2025 Notes of an amount equal to the amount by which the Cash Consideration exceeds the Estimated Cash Consideration (up to an excess equal to the amount of the Working Capital Escrow Amount). To the extent that following such customary adjustment to the Cash Consideration, the Estimated Cash Consideration is greater than the Cash Consideration, Forest Buyer and the Company shall cause the Escrow Agent to make payment to Forest Buyer (or its designees) of an amount equal to the lesser of (i) the amount by which the Estimated Cash Consideration exceeds the Cash Consideration, and (ii) the Working Capital Escrow Amount held in the Working Capital Escrow Account, including any dividends, interest, distributions and other income received in respect thereof, less any losses on investment thereof, less distributions thereof in accordance with the Purchase Agreement and the Escrow Agreement (the “Working Capital Escrow Funds”), in each case, from the Working Capital Escrow Account, and after any such payments are made to Forest Buyer, the remaining Working Capital Escrow Funds (if any) shall be used for the repurchase of 2026 Notes and/or 2025 Notes.

The above description of the Purchase Agreement and the Transactions is not complete and is subject to, and qualified in its entirety by reference to, the full text of the Purchase Agreement, a copy of which was included as Exhibit 2.1 to the November 20 Current Report, and the terms of which are incorporated in this Current Report on Form 8-K (this “Current Report”) by reference.

Item 8.01Other Events.

On March 18, 2024, the Company issued a press release announcing the Closing of the Transactions. A copy of the press release is filed as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

Forward-Looking Statements

This Current Report contains forward-looking statements within the meaning of U.S. federal securities laws. Such forward-looking statements include, but are not limited to, statements regarding the repurchases of the 2026 Notes and 2025 Notes and the availability of funds in the Tax escrow and Working Capital escrow that may be used for this purpose, in each case, including the amounts and timing thereof, the projected operation and financial performance of the Company and its various subsidiaries, including TTC Healthcare, Inc., its product offerings and developments and reception of its product by customers, the hearing before the CFR, including its timing, the


Company’s ability to demonstrate compliance with the listing requirements of the NYSE, the delisting of the Common Stock from the NYSE in the event the Company’s appeal is unsuccessful, the trading of the Company’s Common Stock in the over-the-counter market, and the Company’s expectations, hopes, beliefs, intentions, plans, prospects or strategies regarding the future revenue and the business plans of the Company’s management team. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this Current Report are based on certain assumptions and analyses made by the management of the Company considering their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the ability of the Company to utilize funds in the Notes escrow and Working Capital escrow for the repurchases of the 2026 Notes and 2025 Notes, the ability of the Company to service or otherwise pay its debt obligations following such repurchases, including to holders of the Company’s notes that will remain outstanding, the mix of services utilized by the Company’s customers and such customers’ needs for these services, market acceptance of new service offerings, the ability of the Company to scale and expand what it does for existing customers as well as to add new customers, the outcome of the CFR hearing and whether the CFR will grant the Company’s request for continued listing, whether the Company will be able to regain and sustain compliance with the continued listing standards of the NYSE or comply with the initial listing standards of another national securities exchange, uncertainty with respect to how the International Court of Arbitration or the Indian courts shall decide various matters that are before them or that the board of directors of Glocal Healthcare Systems Private Limited (“Glocal”) will act in compliance with its fiduciary duties to Glocal’s shareholders, and that the Company will have sufficient capital to operate as anticipated. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as may be required under applicable securities laws.


Item 9.01
Financial Statements and Exhibits.

(d) Exhibits.
Exhibit No.Description
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).




SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 18, 2024                         UPHEALTH, INC.

By:
/s/ Martin S.A. Beck
Name:
Martin S. A. Beck
Title:
Chief Executive Officer

EX-99.1 2 exhibit991cloudbreaksalepr.htm EX-99.1 Document
Exhibit 99.1
UPHEALTH COMPLETES SALE OF CLOUDBREAK HEALTH AT $180 MILLION FULL CASH DEAL

DELRAY BEACH, Fla. – March 18, 2024 – UpHealth, Inc. (“we,” “our,” “UpHealth,” or the “Company”) (NYSE: UPHL) today announced that it completed its previously announced sale of Cloudbreak Health, LLC (“Cloudbreak”), best known for its MarttiTM translation offering, to a newly formed entity controlled by GTCR LLC for $180 million in gross cash proceeds on March 15, 2024.

The $180 million in gross proceeds will be used to pay all closing expenses including any potential liability for taxes on the sale and paying down the Company’s debt, including all of the Company’s $115 million 2026 Notes and a substantial portion of its $57.2 million 2025 Notes.

“This transaction is one more critical milestone in the last three years of UpHealth, Inc.’s journey to focus the Company on its strategic core and most profitable businesses. This major restructuring includes so far, shutting down the non-profitable businesses that also presented challenging legal risks, as well as divesting and selling profitable businesses that did not have a good strategic fit to our mission. The sale announced today of Cloudbreak, and the sale of IGI in May 2023 in a $56 million cash deal, have together generated to the Company about $235 million of cash that has allowed us to significantly reduce the liabilities of the Company and enhance its business focus and the financial performance, all resulting in unlocking meaningful value to our stakeholders. Moving forward we will focus solely on the very important purposed behavioral health business as we enhance investments in the profitable TTC Healthcare operation” said Dr Avi Katz, Chairman of the Board of Directors.

“The Cloudbreak sale transaction will significantly deleverage our balance sheet, stabilize our business and empower us to concentrate our resources on TTC Healthcare,” said Martin Beck, Chief Executive Officer. “TTC is a profitable and cash-generating behavioral health business with an incredibly bright future and we look forward to working with our talented team to profitably scale and deliver high-quality care to more patients. We are proud to continue to increase our presence in the behavioral health sector which is one of the most critical healthcare verticals for all U.S. and global citizens, regardless of age, gender, sexual orientation, religion, nationality and ethnicity.”

TTC Healthcare currently provides its patients with a full continuum of evidence-based mental health and substance use disorder services in four facilities with 159 licensed beds in Florida. The business continues to show strong census growth, with an attractive payor mix, including the U.S. Department of Veterans Affairs.

UpHealth will provide a detailed financial analysis of the financial impacts of the Cloudbreak sale on its balance sheet and income statement in our upcoming Annual Report on Form 10-K, expected to be filed before the end of the month.


Additional Detail on the Proceeds from the Sale

The proceeds of the Cloudbreak sale, after transaction-related fees and expenses, have been deposited into three escrow accounts: a Notes escrow ($139 million), a Tax escrow ($27 million) and a Working Capital escrow ($3 million). Funds in the Notes escrow will be released on approximately June 3, 2024, but no later than June 15, 2024, and will be used to satisfy in full, plus accrued interest, the Company’s 2026 Notes and to repurchase approximately $20 million of the Company’s 2025 Notes, plus accrued interest, leaving approximately $37 million of 2025 Notes outstanding, which will constitute the Company’s entire long term debt. Funds in the Tax escrow will be used to satisfy the Company’s 2024 tax liability and any funds not required for this purpose will be used to repurchase additional 2025 Notes. Funds in the Working Capital escrow will be used to satisfy any obligations of the Company resulting from a


difference between Cloudbreak’s targeted and actual working capital as of the closing of the transaction, and any funds not used for this purpose will also be used to repurchase additional 2025 Notes.

About UpHealth, Inc.

UpHealth, Inc. is a leading provider of a full continuum of behavioral health solutions through the utilization of evidence-based treatments and services. Operating through its TTC Healthcare, Inc. subsidiary, UpHealth targets mental health issues and substance use disorders with services provided by psychiatrists, physicians, neurologists, licensed therapists, and clinical social workers. The Company’s levels of care include detox, residential, partial hospitalization programs, intensive outpatient programs, outpatient, and telehealth. UpHealth’s clients include health plans, healthcare providers and community-based organizations. For more information, please visit https://uphealthinc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Such forward-looking statements include, but are not limited to, statements regarding the repurchases of the 2026 Notes and 2025 Notes and the availability of funds in the Tax escrow and Working Capital escrow that may be used for this purpose, in each case, including the amounts and timing thereof, the projected operation and financial performance of the Company and its various subsidiaries, including TTC Healthcare, its product offerings and developments and reception of its product by customers, and the Company’s expectations, hopes, beliefs, intentions, plans, prospects or strategies regarding the future revenue and the business plans of the Company’s management team. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company considering their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the ability of the Company to utilize funds in the Notes escrow and Working Capital escrow for the repurchases of the 2026 Notes and 2025 Notes, the ability of the Company to service or otherwise pay its debt obligations following such repurchases, including to holders of the Company’s notes that will remain outstanding, the mix of services utilized by the Company’s customers and such customers’ needs for these services, market acceptance of new service offerings, the ability of the Company to scale and expand what it does for existing customers as well as to add new customers, whether the Company will be able to regain and sustain compliance with the continued listing standards of the NYSE or comply with the initial listing standards of another national securities exchange, uncertainty with respect to how the International Court of Arbitration or the Indian courts shall decide various matters that are before them or that the board of directors of Glocal Healthcare Systems Private Limited (“Glocal”) will act in compliance with its fiduciary duties to Glocal’s shareholders, and that the Company will have sufficient capital to operate as anticipated. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company undertakes no obligation to update or revise any


forward-looking statements, whether because of new information, future events, or otherwise, except as may be required under applicable securities laws.

Contact

Jude Gorman / Dan Moore
Collected Strategies
UPH-CS@collectedstrategies.com


 EX-101.SCH 3 uph-20240315.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 uph-20240315_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 uph-20240315_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 15, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Mar. 15, 2024
Entity Registrant Name UpHealth, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38924
Entity Tax Identification Number 83-3838045
Entity Address, Address Line One 14000 S. Military Trail
Entity Address, Address Line Two Suite 203
Entity Address, City or Town Delray Beach
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33484
City Area Code 888
Local Phone Number 424-3646
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol UPH(1)
Security Exchange Name NYSE
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001770141
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://uphealthinc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports uph-20240315.htm uph-20240315.xsd uph-20240315_lab.xml uph-20240315_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "uph-20240315.htm": { "nsprefix": "uph", "nsuri": "http://uphealthinc.com/20240315", "dts": { "inline": { "local": [ "uph-20240315.htm" ] }, "schema": { "local": [ "uph-20240315.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "uph-20240315_lab.xml" ] }, "presentationLink": { "local": [ "uph-20240315_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://uphealthinc.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "uph-20240315.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "uph-20240315.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001770141-24-000020-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001770141-24-000020-xbrl.zip M4$L#!!0 ( -E#! (@[ > 97AH:6)I=#DY,6-L;W5D M8G)E86MS86QE<'(N:'1M[5M=<]PVLGW?7X&UO=FD:F:LD:S(EKVN4F0Y]D:. M799\4_NT!9+@$!&'F 7 &8U__3W= #B<+V53E4V\NMY%9)KPK1.MU,Q$^%$3\9.Q-WHNPWNO?:U>IGE>/ Z_OWC,B[S(3+%\^:+07M?K;@ZENAI4B M 4Y/#F?^^4(7OCH='QS\Y<':=U[=^J&L]:0Y97'QMC387'R=F]K8TX<'_.E?K_54.?&C6HB/9BJ;OPZ<;-S0*:O+\*'3GQ56Q.+\ZR)*@WEJ MW:@DW?B01+JXK72FO7CV;#1^\9B^3WO:VEE/XASJ4_8W%_GPET0>'T+D3Q_> M7)Q=7K\1Y^_??;B\N+ZX$E=GEQ?B_6MQ?OG^TZOO/EZ<_2#B-V?7XM'XZ8%X M]_;R\NW['\7K3Y>7XOSLZHUXA0_$^I9W;_;GUGE=+N-N@1/[\M^^)D,K^96-,VQ3!*5O*?Y[^7G%\]?'HX M'C\7[Z3-*S%^.F"W_8-%?;)35)%D_31[HV2]2\;?2Q1?#<3;)A^)KTFFPX/G M"S7@GR!=?&):N_DHR(VQZ;FQPE_T<,<#(:'_\;)G@^ M,TY[;4#>JI9>S]5S;V:GPZ/14QH^5];K7-:1"C+I%,WPX.7UNS\2-L);C"9Y M30-KE)BEF0Q@5R%%HQ:P�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uph-20240315_htm.xml IDEA: XBRL DOCUMENT 0001770141 2024-03-15 2024-03-15 0001770141 false 8-K 2024-03-15 UpHealth, Inc. DE 001-38924 83-3838045 14000 S. Military Trail Suite 203 Delray Beach FL 33484 888 424-3646 false false false false Common Stock, par value $0.0001 per share UPH(1) NYSE true false